{"organizations": [], "uuid": "30db4753e03bf9e83649ac9c4706b9f278eb78d5", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "", "site_section": "http://www.cnbc.com/id/10000027/page/4", "section_title": "Press Releases - CNBC", "url": "http://www.cnbc.com/2018/02/21/business-wire-concert-pharmaceuticals-to-report-full-year-2017-results-on-march-1-2018.html", "country": "US", "domain_rank": 767, "title": "Concert Pharmaceuticals to Report Full Year 2017 Results on March 1, 2018", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.007, "site_type": "news", "published": "2018-02-21T15:00:00.000+02:00", "replies_count": 0, "uuid": "30db4753e03bf9e83649ac9c4706b9f278eb78d5"}, "author": "cnbc.com", "url": "http://www.cnbc.com/2018/02/21/business-wire-concert-pharmaceuticals-to-report-full-year-2017-results-on-march-1-2018.html", "ord_in_thread": 0, "title": "Concert Pharmaceuticals to Report Full Year 2017 Results on March 1, 2018", "locations": [], "entities": {"persons": [], "locations": [{"name": "mass.", "sentiment": "none"}, {"name": "lexington", "sentiment": "none"}, {"name": "canada", "sentiment": "none"}, {"name": "u.s.", "sentiment": "none"}], "organizations": [{"name": "concert pharmaceuticals, inc.", "sentiment": "neutral"}, {"name": "company", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "LEXINGTON, Mass.--(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will report its financial results for the year ended December 31, 2017, on Thursday, March 1, 2018, before the U.S. financial markets open. The Company will host a conference call and webcast at 8:30 a.m. ET to discuss 2017 financial results and provide a business update. Individuals interested in participating in the call should dial (855) 354-1855 (U.S. and Canada) or (484) 365-2865 (International).\nA live webcast may be accessed in the Investors section of the Company’s website at www.concertpharma.com . Please log on to the Concert website approximately 15 minutes prior to the scheduled webcast to ensure adequate time for any software downloads that may be required. A replay of the webcast will be available on Concert’s website for three months.\nAbout Concert\nConcert Pharmaceuticals is a clinical stage biopharmaceutical company focused on applying its DCE Platform® (deuterated chemical entity platform) to create novel medicines designed to address unmet patient needs. The Company’s approach starts with approved drugs in which deuterium substitution has the potential to enhance clinical safety, tolerability or efficacy. Concert has a broad pipeline of innovative medicines targeting autoimmune and inflammatory diseases and central nervous systems (CNS) disorders. For more information please visit www.concertpharma.com or follow us on Twitter at @ConcertPharma or on LinkedIn .\nConcert Pharmaceuticals Inc., the CoNCERT Pharmaceuticals Inc. logo and DCE Platform are registered trademarks of Concert Pharmaceuticals, Inc.\nView source version on businesswire.com : http://www.businesswire.com/news/home/20180221005091/en/\nConcert Pharmaceuticals, Inc.\nJustine Koenigsberg, 781-674-5284\nir@concertpharma.com\nSource: Concert Pharmaceuticals, Inc.", "external_links": ["http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fir.concertpharma.com%2Fevents.cfm&esheet=51760650&newsitemid=20180221005091&lan=en-US&anchor=Investors&index=2&md5=1e9aac332983712189d04c97c89f33a8", "http://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Ftwitter.com%2FConcertPharma&esheet=51760650&newsitemid=20180221005091&lan=en-US&anchor=%40ConcertPharma&index=8&md5=6713be23adabaceb0e644c40314db4a5", "http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.concertpharma.com&esheet=51760650&newsitemid=20180221005091&lan=en-US&anchor=Concert+Pharmaceuticals&index=4&md5=0104b7670560473271ac23f9255e0f2f", "http://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2F73234%2F&esheet=51760650&newsitemid=20180221005091&lan=en-US&anchor=LinkedIn&index=9&md5=15e1a168b0fc5ed8975d4b5791e1a453", "http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.concertpharma.com%2F&esheet=51760650&newsitemid=20180221005091&lan=en-US&anchor=Concert+Pharmaceuticals%2C+Inc.&index=1&md5=83f22088db5d5618f4d9154544ff4b93", "http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.concertpharma.com%2Fproduct-pipeline%2F&esheet=51760650&newsitemid=20180221005091&lan=en-US&anchor=broad+pipeline&index=6&md5=42a2403aa8e13f90cfe3fac401d78080", "http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.concertpharma.com&esheet=51760650&newsitemid=20180221005091&lan=en-US&anchor=www.concertpharma.com&index=3&md5=096e0e6672b5fb809270d11d83c3d663", "http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.concertpharma.com%2F&esheet=51760650&newsitemid=20180221005091&lan=en-US&anchor=www.concertpharma.com&index=7&md5=351b743f9f468e018d7714d3efa0e63e", "http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.concertpharma.com%2Ftechnology-overview%2Fdce-platform%2F&esheet=51760650&newsitemid=20180221005091&lan=en-US&anchor=DCE+Platform%C2%AE&index=5&md5=addbda23ac33fd5248531255a128e804", "http://www.businesswire.com/news/home/20180221005091/en/"], "published": "2018-02-21T15:00:00.000+02:00", "crawled": "2018-02-21T15:49:28.041+02:00", "highlightTitle": ""}